Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Loncastuximab Tesirine for Patients with Relapsed or Refractory Mantle Cell Lymphoma After Immunochemotherapy with Rituximab, Bendamustine, and Cytarabine

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Mantle Cell Lymphoma (MCL), which is a rare form of non-Hodgkin's lymphoma. The study is investigating the effectiveness of a treatment called loncastuximab tesirine, also known by its code name ADCT-402. This treatment is being tested in patients who have previously been treated with or are intolerant to a type of medication known as Bruton Tyrosine Kinase inhibitors (BTKi). The trial aims to see how well loncastuximab tesirine works when used after a short course of a combination of drugs called Rituximab, Bendamustine, and Cytarabine, collectively referred to as R-BAC.

Participants in the study will receive the treatment through an intravenous method, which means the medication is given directly into a vein. The study will follow the participants over a period to observe the effects of the treatment on their condition. The main goal is to assess how long patients can go without their disease getting worse after receiving the treatment. The study will also look at other outcomes, such as overall survival, which is the length of time patients live after starting the treatment, and the rate at which patients' conditions improve or stabilize.

Throughout the study, researchers will monitor for any side effects or adverse events that may occur. This information will help determine the safety and effectiveness of loncastuximab tesirine as a treatment option for patients with relapsed or refractory Mantle Cell Lymphoma. The study is designed to provide valuable insights into whether this treatment can offer a new option for patients who have limited choices due to their previous treatments.

The research process

The trial runs in 3 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    The initial treatment phase involves two courses of a combination therapy known as R-BAC. This includes the medications rituximab, bendamustine hydrochloride, and cytarabine. All medications are administered through an intravenous route.

    The purpose of this phase is to prepare for the subsequent consolidation treatment. The specific dosage and frequency of administration will be determined by the healthcare provider based on individual patient needs.

  2. Step 2

    Consolidation treatment

    Following the initial treatment phase, the consolidation treatment begins. This involves the administration of loncastuximab tesirine, also given intravenously.

    The goal of this phase is to enhance the effectiveness of the initial treatment and to help maintain the response achieved. The duration and specific schedule of this treatment will be provided by the healthcare team.

  3. Step 3

    Monitoring and follow-up

    After completing the consolidation treatment, regular monitoring and follow-up appointments are scheduled. These appointments are crucial for assessing the response to treatment and for early detection of any recurrence or progression of the disease.

    During these visits, various assessments may be conducted, including imaging tests and blood work, to evaluate the patient's condition and to ensure the treatment's effectiveness.

Who can join the trial?

19 criteria

  • Must have a confirmed diagnosis of Mantle Cell Lymphoma (MCL) according to the 2017 World Health Organization classification.
  • Must have a performance status of 2 or less on the ECOG/WHO scale, which measures how well a person can perform daily activities, unless the status is related to MCL.
  • Must have certain laboratory test results at screening, unless affected by lymphoma in the bone marrow:
    • Absolute neutrophil count (ANC) greater than 1.0 x 109/L.
    • Platelet count of at least 75,000 per mm3.
    • Creatinine clearance of at least 40 mL/min, which measures kidney function.
    • Aspartate transaminase (AST) and alanine transaminase (ALT) levels no more than 3 times the upper limit of normal (ULN), which are liver enzymes.
    • Bilirubin level no more than 1.5 times the ULN, unless the increase is due to Gilbert's syndrome or a non-liver-related cause.
    • Must understand and voluntarily sign an informed consent form approved by the National Ethic Committee before any study procedures begin.
    • Must be able to follow the study visit schedule and other study requirements.
    • Must have a life expectancy of at least 3 months.
    • Women who can have children must agree to use effective birth control if sexually active, from signing the consent form until at least 10 months after the last dose of the study drug. Men with female partners who can have children must also agree to use effective birth control if sexually active, from signing the consent form until at least 7 months after the last dose of the study drug.
    • Must be between 18 and 84 years old.
    • Must have relapsed or refractory disease after one to four previous treatments.
    • Must be either new to bendamustine treatment or have relapsed at least one year after the last cycle of a bendamustine-containing treatment.
    • Must have had previous treatment with Bruton Tyrosine Kinase inhibitors (BTKi) alone or in combination, and have relapsed or refractory disease, or have stopped BTKi treatment due to side effects and need treatment for active disease.
    • Previous treatment with any anti-CD19 agents, including CAR-T treatment, is allowed. If treated with anti-CD19, CD19 expression must be checked by histology or flow cytometry.
    • Patients treated with venetoclax are allowed.
    • Patients eligible for stem cell transplant are allowed.
    • Must have measurable disease in lymph nodes or outside of lymph nodes that is at least 1.5 cm in the longest diameter and measurable in two directions. Patients with only bone marrow involvement are eligible, but bone marrow aspiration and biopsy are required for all evaluations.

Who cannot join the trial?

6 criteria

  • Patients who have not been treated with Bruton Tyrosine Kinase inhibitors (BTKi) or are not intolerant to BTKi.
  • Patients who have not experienced a return or worsening of their Mantle Cell Lymphoma after previous treatment.
  • Patients who have not received salvage immunochemotherapy, specifically 2 courses of Rituximab-Bendamustine-Cytarabine (R-BAC).
  • Patients who are not within the specified age range for the study.
  • Patients who do not meet the gender requirements for the study.
  • Patients who are part of a vulnerable population that is not selected for this study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Loncastuximab Tesirine

    is a medication being studied for its effectiveness in treating patients with Mantle Cell Lymphoma who have already been treated with or are intolerant to Bruton Tyrosine Kinase inhibitors. It is used as a consolidation therapy, which means it is given after initial treatment to help strengthen the response to the treatment and potentially improve outcomes.

  • Rituximab

    is a medication used in combination with other drugs as part of the initial treatment for Mantle Cell Lymphoma. It works by targeting specific cells in the immune system to help fight the cancer.

  • Bendamustine

    is a chemotherapy drug that is used alongside other medications to treat Mantle Cell Lymphoma. It helps to kill cancer cells and reduce the size of tumors.

  • Cytarabine

    is another chemotherapy medication used in combination with other drugs to treat Mantle Cell Lymphoma. It works by interfering with the growth of cancer cells, slowing down or stopping their spread.

What is already known about the treatment

Loncastuximab Tesirine – This medication is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating mantle cell lymphoma, particularly in patients who have relapsed or are intolerant to Bruton Tyrosine Kinase inhibitors. It is an antibody-drug conjugate, which means it combines an antibody with a drug to specifically target and kill cancer cells. The main therapeutic indication is for mantle cell lymphoma, a type of non-Hodgkin lymphoma. At the molecular level, it works by binding to a specific protein on the surface of cancer cells, delivering a toxic payload that disrupts the DNA of these cells, leading to their death. It is classified pharmacologically as an antineoplastic agent.

Investigated diseases

Mantle Cell Lymphoma – Mantle cell lymphoma is a type of non-Hodgkin lymphoma that originates from B-cells, a kind of white blood cell. It typically begins in the lymph nodes but can also affect other areas such as the spleen, bone marrow, and digestive tract. The disease is characterized by the overproduction of abnormal B-cells, which can lead to the enlargement of lymph nodes and other organs. As it progresses, it may cause symptoms like fatigue, fever, night sweats, and weight loss. The disease can vary in its rate of progression, with some cases advancing slowly while others may progress more rapidly.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-511633-35-00Protocol codeFIL_COLUMNEstimated enrolment49 patientsSponsorFondazione Italiana Linfomi Ets

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.